Teva moves anti-IL-15 antibody to Phase 2b for vitiligo treatment

This is a summary. Read the complete story at Investing.com below.

Related Stories

stocksabout 1 hour ago

Berkshire Hathaway speeds up stock buybacks, though profit falls

Investing.com

stocksabout 1 hour ago

National Australia Bank names Ian Saines as next chair

Investing.com

stocksabout 1 hour ago

Wall St futures mixed amid AI spending concerns; inflation data awaited

Investing.com